Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions

Immunologic Human Renal Allograft Injury Associates with an Altered IL-10/TNF-  Expression Ratio in Regulatory B Cells

(2014) A. Cherukuri et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

(2014) Loïc Guillevin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis

(2014) S. K. Todd et al.   RHEUMATOLOGY

Regulatory B cells in ANCA-associated vasculitis

(2013) B Wilde et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides

(2013) Jens Thiel et al.   AUTOIMMUNITY

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress

(2013) Md Yuzaiful Md Yusof et al.   Expert Review of Clinical Immunology

Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre

(2013) Emilio Besada et al.   RHEUMATOLOGY

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center

(2012) Rodrigo Cartin-Ceba et al.   ARTHRITIS AND RHEUMATISM

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis

(2012) Rona M. Smith et al.   ARTHRITIS AND RHEUMATISM

Maintenance of clinical remission in ANCA-associated vasculitis

(2012) Raashid Luqmani   Nature Reviews Rheumatology

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

(2011) P. Emery et al.   RHEUMATOLOGY

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis

(2011) M.-J. C. J. Guerry et al.   RHEUMATOLOGY

Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment

(2010) E. M. Vital et al.   ARTHRITIS AND RHEUMATISM

Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

(2010) E. P. Rhee et al.   Clinical Journal of the American Society of Nephrology

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

(2008) C Mukhtyar et al.   ANNALS OF THE RHEUMATIC DISEASES

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

(2008) Shouvik Dass et al.   ARTHRITIS AND RHEUMATISM